27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Boston Scientific (NYSE: BSX) announces its next round of earnings this Thursday, July 28, 2011. Get prepared with Benzinga's ultimate preview for Boston Scientific's second quarter earnings.
Earnings and Revenue:
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Analysts are predicting an EPS reading of 8 cents per share and revenues of $1.94 billion. Wall Street will be looking to see how this quarter's numbers compare to the year-ago quarter's positive EPS of 6 cents per share on revenues of $1.93 billion. We'll have to wait for Thursday to see if Boston Scientific has accomplished the estimated 33.3% rise in EPS and 0.5% increase in revenues on a year-over-year basis.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 | Q4 | Q3 | Q2 |
| EPS Estimate | $0.04 | $0.10 | $0.06 | $0.03 |
| EPS Actual | $0.14 | $0.20 | $0.12 | $0.06 |
Stock Performance:
At last check, shares of Boston Scientific were trading at $7.21. Shares are down 4.8% year to date. For a full 12 months, the return has risen by 17.6%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
- Long-term shareholders are already enjoying 12-month gains prior to the announcement
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Average Stock Rating:
The average rating by analysts for Boston Scientific is a Hold. This rating has strengthened slightly over the past ninety days.
Competitors:
Want to check out the performance of Boston Scientific closest competitors? Take a look at some of the company's peers in the healthcare sector.
- Abbott Laboratories (NYSE: ABT): Hold with a $1.12 recent quarter EPS
- C.R. Bard (NYSE: BCR): Hold with a $1.57 recent quarter EPS
- Johnson & Johnson (NYSE: JNJ): Moderate Buy with a $1.28 recent quarter EPS
- Medtronic (NYSE: MDT): Hold with a $0.90 recent quarter EPS
Boston Scientific is in the medical products industry, which has experienced price/earnings growth of 1.5%.
Finally, a description of the company's main areas of operation: Boston Scientific offers medical devices used in interventional cardiology, cardiac rhythm management, peripheral interventions, endoscopy, gynecology, electrophysiology, neurovascular intervention and neuromodulation.
Take Action:
That's your advanced look at Boston Scientific's upcoming earnings numbers -- be ready to take quick action if the company's report contains any surprises. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.
- To see up-to-date news on Boston Scientific, click here
- To see other trading ideas, click here
- To see other company earnings recaps, click here
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.